Find trials
Search tips

Aromatase Inhibitor Therapy Impact on Glucose Homeostasis and Diabetes Risk

Overview

About this study

Assess the impact of endocrine adjuvant therapy with aromatase inhibitors in women with hormone receptor positive breast cancer, on various indices of glucose homeostasis, utilizing oral minimal model assessment, in comparison to healthy post menopausal women and another cohort of women on tamoxifen.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria: 

  • Women aged 18-85.
  • Women with non-metastatic breast cancer.
  • Further stratification will be done based on aromatase inhibitor therapy use.

Exclusion Criteria: 

  • Established diagnosis of diabetes,
  • Therapy with anti-hyperglycemic medications that could affect glucose metabolism.
  • Screening fasting glucose ≥ 126 mg/dl, and/or HbA1c ≥ 6.5%.
  • History of bariatric or similar malabsorptive surgery.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 5/30/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Kalpana Muthusamy, M.B.B.S., M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available

More about research at Mayo Clinic

.
CLS-20556005

Mayo Clinic Footer